Drug-induced Weight Gain

Drug-induced Weight Gain


A common side effect of certain antidiabetic drugs, for example, thiazolidinediones suchas pioglitazone, is weight gain. This is a serious disadvantage in the clinic as many diabetic patients are overweight or obese and further weight gain is undesirable. Animal models can be used to explore the potential of novel antidiabetic drugs to produce weight gain in man. For example, pioglitazone increases body weight in dietary-induced obese rats.


Drug-induced weight-gain is also a serious side effect of certain atypical (second generation) antipsychotic drugs such as olanzapine. We have used therefore developed an animal model of antipsychotic-induced weight gain (neuroleptic-induced weight gain) that can be used to investigate the effects of novel antipsychotic drugs on body weight.


Antipsychotic-induced Weight Gain in the Rat


The effects of drug-induced weight gain on a variety of other parameters including glycaemic control and adiposity can also be examined. For example, the oral glucose tolerance test (OGTT) performed on Day 15 of the above study demonstrated that repeated olanzapine treatment impaired glucose tolerance in female rats on a high fat diet.


These animal models can also be used to explore whether novel antiobesity agents can prevent the increase in body weight produced by other drug treatments.


Please contact us for further information about our animal models of drug-induced weight gain.




Grempler et al. 2011. The novel SGLT-2 inhibitor BI 10773 (empagliflozin) prevents pioglitazone-induced weight gain and further improves glycemic control in dietary-induced obese rats. Abstract No. 1851-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.


Heal et al. 2008. Prevention of antipsychotic-induced weight-gain by the 5-HT6 agonist, E-6837. Program No. 584.12. Society for Neuroscience Meeting, Washington, DC, 15th-19th November 2008.




Heal et al. 2012. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity. In: Current Antipsychotics, Handb Exp Pharmacol Vol 212, G Gross and MA Geyer (Eds), Springer, pp135-164. [PubMed]